These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 21788641)

  • 1. Comment on: Pantalone et al. The risk of overall mortality in patients with type 2 diabetes receiving glipizide, glyburide, or glimepiride monotherapy: a retrospective analysis. Diabetes Care 2010;33:1224-1229.
    Khalangot MD
    Diabetes Care; 2011 Aug; 34(8):e138; author reply 139. PubMed ID: 21788641
    [No Abstract]   [Full Text] [Related]  

  • 2. Increase in overall mortality risk in patients with type 2 diabetes receiving glipizide, glyburide or glimepiride monotherapy versus metformin: a retrospective analysis.
    Pantalone KM; Kattan MW; Yu C; Wells BJ; Arrigain S; Jain A; Atreja A; Zimmerman RS
    Diabetes Obes Metab; 2012 Sep; 14(9):803-9. PubMed ID: 22486923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The risk of overall mortality in patients with type 2 diabetes receiving glipizide, glyburide, or glimepiride monotherapy: a retrospective analysis.
    Pantalone KM; Kattan MW; Yu C; Wells BJ; Arrigain S; Jain A; Atreja A; Zimmerman RS
    Diabetes Care; 2010 Jun; 33(6):1224-9. PubMed ID: 20215447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of mortality and cardiovascular event risk associated with various insulin secretagogues: A nationwide real-world analysis.
    Huang HK; Yeh JI
    Diabetes Res Clin Pract; 2019 Jun; 152():103-110. PubMed ID: 31108137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The risk of overall mortality in patients with Type 2 diabetes receiving different combinations of sulfonylureas and metformin: a retrospective analysis.
    Pantalone KM; Kattan MW; Yu C; Wells BJ; Arrigain S; Nutter B; Jain A; Atreja A; Zimmerman RS
    Diabet Med; 2012 Aug; 29(8):1029-35. PubMed ID: 22248043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pantalone et al.: the risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis.
    Bell DS
    Acta Diabetol; 2009 Jun; 46(2):155; author reply 157. PubMed ID: 19300899
    [No Abstract]   [Full Text] [Related]  

  • 7. Potential CYP2C9-mediated drug-drug interactions in hospitalized type 2 diabetes mellitus patients treated with the sulphonylureas glibenclamide, glimepiride or glipizide.
    Tirkkonen T; Heikkilä P; Huupponen R; Laine K
    J Intern Med; 2010 Oct; 268(4):359-66. PubMed ID: 20698928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glimepiride. A review of its use in the management of type 2 diabetes mellitus.
    Langtry HD; Balfour JA
    Drugs; 1998 Apr; 55(4):563-84. PubMed ID: 9561345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sulfonylurea treatment of type 2 diabetes mellitus: focus on glimepiride.
    Korytkowski MT
    Pharmacotherapy; 2004 May; 24(5):606-20. PubMed ID: 15162895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of oral glucose-lowering drugs on long term outcomes in patients with diabetes mellitus following myocardial infarction not treated with emergent percutaneous coronary intervention--a retrospective nationwide cohort study.
    Jørgensen CH; Gislason GH; Andersson C; Ahlehoff O; Charlot M; Schramm TK; Vaag A; Abildstrøm SZ; Torp-Pedersen C; Hansen PR
    Cardiovasc Diabetol; 2010 Sep; 9():54. PubMed ID: 20843380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analyses of the conversion of patients with non-insulin-dependent diabetes mellitus from glipizide to glyburide and of the accompanying pharmacy follow-up clinic.
    Law AV; Pathak DS; Segraves AM; Weinstein CR; Arneson WH
    Clin Ther; 1995; 17(5):977-87. PubMed ID: 8595649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral hypoglycaemic agents and the development of non-fatal cardiovascular events in patients with type 2 diabetes mellitus.
    Hung YC; Lin CC; Wang TY; Chang MP; Sung FC; Chen CC
    Diabetes Metab Res Rev; 2013 Nov; 29(8):673-9. PubMed ID: 23956007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative effectiveness of hypoglycemic medications among veterans.
    Kheirbek RE; Alemi F; Zargoush M
    J Manag Care Pharm; 2013; 19(9):740-4. PubMed ID: 24156642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Probable hypoglycemic adverse drug reaction associated with prickly pear cactus, glipizide, and metformin in a patient with type 2 diabetes mellitus.
    Sobieraj DM; Freyer CW
    Ann Pharmacother; 2010; 44(7-8):1334-7. PubMed ID: 20516361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metformin in combination with various insulin secretagogues in type 2 diabetes and associated risk of cardiovascular morbidity and mortality--a retrospective nationwide study.
    Mogensen UM; Andersson C; Fosbøl EL; Schramm TK; Vaag A; Scheller NM; Torp-Pedersen C; Gislason G; Køber L
    Diabetes Res Clin Pract; 2015 Jan; 107(1):104-12. PubMed ID: 25458330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prospective trial of risk factors for sulfonylurea-induced hypoglycemia in type 2 diabetes mellitus.
    Burge MR; Schmitz-Fiorentino K; Fischette C; Qualls CR; Schade DS
    JAMA; 1998 Jan; 279(2):137-43. PubMed ID: 9440664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Glimepiride--an oral antidiabetic agent].
    Becić F; Kapić E; Becić E
    Med Arh; 2003; 57(2):125-7. PubMed ID: 12822388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An overview of the safety and tolerance of glimepiride.
    Schneider J
    Horm Metab Res; 1996 Sep; 28(9):413-8. PubMed ID: 8911975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study.
    Schramm TK; Gislason GH; Vaag A; Rasmussen JN; Folke F; Hansen ML; Fosbøl EL; Køber L; Norgaard ML; Madsen M; Hansen PR; Torp-Pedersen C
    Eur Heart J; 2011 Aug; 32(15):1900-8. PubMed ID: 21471135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.